还剩2页未读,继续阅读
文本内容:
胃癌术后Xelox方案同期联合适形调强放疗的临床观察胃癌术后Xelox方案同期联合适形调强放疗的临床观察作者杜小波蒲静赵振华戴堂知廖东彪李雪松周筱秋任素蓉目的:评价胃癌患者术后CapeOX方案同期联合调强放疗的近期疗效和毒性反应方法从xx年9月至xx年9月,41例胃癌术后患者采用化疗采用Xelox方案,卡培他滨1250mg/m2,口服2次/d,1-14d;奥沙利铂130mg/m2,持续静脉滴注2~3h,1d同步适形调强放疗,靶区包括瘤床和区域淋巴引流区放化疗后辅助化疗以Xelox方案4~6疗程,观察近期疗效及毒性反应结果全组1年总生存率、无复发生存率和局部区域控制率分别为90.2%、80.5%和
95.1%有3例中断同步放化疗Ⅲ度骨髓抑制4例,Ⅲ度胃肠道反应5例结论胃癌患者术后CapeOX方案同期联合调强放疗的近期疗效较好,毒性反应是可耐受的胃癌;放疗;卡培他滨;奥沙利铂;副作用Objective;Toevaluatetheshort-termefficacyandtoxicityofXeloxplusconcurrentconformalintensitymodulatedradiationtherapyforpostoperationpatientswithgastriccancer.Methods:FormSeptemberxxtoSeptemberxx41postoperationgastriccancerpatientsweretreatedwithXeloxplusconcurrentconformalintensitymodulatedradiationtherapy.TheXeloxregimenwascapecitabine1250mg/m2orallybidday1to14oxaliplatin130mg/m2continuousinfusion2to3hday
1.Intensitymodulatedradiationtherapy:targetvolumeincludingthetumorbedandregionallympha...。